The search for potential cure next to angiogenesis-dependent diseases is focused on plants because the active compounds derived from natural sources are inherently better tolerated in the body and have lower side effects than the synthetic drugs. The leaf, stem bark and stem powders of Holoptelea integrifolia were extracted separately by various solvents with an increasing order of their polarity. Preliminary phytochemical screening of methanol extracts of leaf, stem bark and stem of Holoptelea integrifolia reveals that among all the 3 extracts of Stem methanol extract of Holoptelea integrifolia (HISME) has shown greater accumulation of phytoconstituents and they are alkaloids, flavonoids, tannins, amino acids, proteins, terpenoids, steroids and carbohydrate followed by Leaf methanol extract of Holoptelea integrifolia (HILME) has shown presence of alkaloids, glycosides, tannins, amino acids, proteins, terpenoids, steroids and carbohydrates and Bark methanol extract Holoptelea integrifolia (HIBME) has tannins, steroids and carbohydrates. The in vitro cytotoxic assay-MTT assay for 3 methanol extracts of H.integrifolia against RAW 264.7, MCF-7cell lines has performed, data reveals that HILME-10µg/ml (63.59± 0.244) has shown highest cytotoxicity against RAW 264.7,HISME - 1µg/ml (83.89± 0.07) has shown highest cytotoxicity against MCF-7 cell lines. HILME, HIBME and HISME were undergone for in ovo chick chorioallantoic membrane (CAM) assay to determine their anti-angiogenic potential. Among all the 3 extracts 2 extracts exhibited inhibition of angiogenesis with the highest activity observed by HILME (64.84± 0.98- 100µg/mL) followed by HIBME ((63.92± 1.16-100µg/mL) it has a comparable activity with known anti-angiogenic agents Sunitinib 1µM (83.1± 0.75), Sorafenib 1µM (77.62± 0.98). The results suggests that Holoptelea integrifolia leaf and stem bark extracts can be a potential source of anti-angiogenic compound for the design and development of drugs targeting angiogenesis- dependent diseases.